Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)

Cannot have received: immune-mediated therapy

Prior exposure to any immune-mediated therapy

Cannot have received: any anti-cancer therapy

Exception: within 28 days prior to the first dose of study intervention or within 5 half-lives of the respective agent, whichever is longer (sub-studies 1-4)

For sub-study 1,2,3,4, participants are ineligible if they have received any anti-cancer therapy within 28 days prior to the first dose of study intervention or within 5 half-lives of the respective agent, whichever is longer.

Cannot have received: systemic therapy, non-palliative radiotherapy, radical pleuropneumonectomy

For substudy 5: Participants with any prior systemic therapy, non-palliative radiotherapy, radical pleuropneumonectomy for pleural mesothelioma.

Cannot have received: radiotherapy

Exception: within 2 weeks prior to enrollment (sub-study 2)

For sub-study 2, have had radiotherapy within 2 weeks prior to enrollment.

Cannot have received: chemotherapy (5-FU, paclitaxel, carboplatin) (5-FU, paclitaxel, carboplatin)

Exception: contraindications to any of these drugs (sub-studies 3,4)

For sub-study 3,4, participants have contraindications to any of the following drugs: 5-FU, paclitaxel and carboplatin